Table 2.
Univariate analysis of clinical, hormonal and morphologic features, according to the acromegaly outcome and treatment groups
| m-Peg-V monotherapy | Peg-V plus SSA | Pasireotide Lar | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Controlled | Active | p-value | Controlled | Active | p-value | Controlled | Active | p-value | |
| Age at acro-diagnosis, median (IQR) | 32 (13) | 41 (20) | 0.94 | 29 (19) | 38 (15) | 0.38 | 38.5 (35) | 60 (20) | 0.723 |
| Gender | |||||||||
| Females n, (%) | 8 (36.4%) | 3 (27.3%) | 0.486 | 11 (47.8%) | 6 (46.2%) | 0.923 | 8 (34.8%) | 5 (62.5%) | 0.182 |
| Males n, (%) | 14 (63.6%) | 8 (72.7%) | 12 (52.2%) | 7 (53.8%) | 15 (65.2%) | 3 (37.5%) | |||
| BMI Kg/m2, median (IQR) | 28 (4) | 27 (1) | 0.98 | 31 (6) | 32 (8) | 0.23 | 30 (4) | 29 (1) | 0.711 |
| GH at acro-diagnosis | 6.5 (14) | 15 (20) | 0.104 | 6.2 (4.3) | 30 (10) | 0.37 | 4 (4) | 7.4 (14) | 0.381 |
| ng/mL, median (IQR) | |||||||||
| IGF-I x ULN at acro-diagnosis, median (IQR) | 2.2 (1) | 3.7 (2) | 0.765 | 3.4 (2) | 4.1 (1.5) | 0.178 | 2.4 (1.5) | 3 (2.4) | 0.368 |
| Tumor dimension | |||||||||
| Micro-adenoma n, (%) | 5 (22.7%) | 2 (18.2%) | 0.523 | 7 (30.4%) | 0 (0%) | 0.03 | 3 (13%) | 1 (2.5%) | 0.691 |
| Macro-adenoma n, (%) | 17 (77.3%) | 9 (81.8%) | 16 (69.6%) | 13 (100%) | 20 (87%) | 7 (87.5%) | |||
| Invasive tumour | |||||||||
| Yes n, (%) | 4 (18.2%) | 3 (27.3%) | 0.547 | 10 (43.5%) | 9 (69.2%) | 0.137 | 17 (73.9%) | 5 (62.5%) | 0.374 |
| No n, (%) | 18 (81.8%) | 8 (72.7%) | 13 (56.5%) | 4 (30.8%) | 6 (26.1%) | 3 (37.5%) | |||
| Residual disease | |||||||||
| Yes n, (%) | 17 (77.3%) | 10 (91%) | 0.338 | 14 (60.9%) | 11 (84.9%) | 0.133 | 19 (82.6%) | 7 (87.5%) | 0.65 |
| No n, (%) | 5 (22.7%) | 1 (9%) | 9 (39.1%) | 2 (15.4%) | 4 (17.4%) | 1 (12.5%) | |||
| Response to first generation SSA | |||||||||
| Partial n, (%) | 13 (59.1%) | 6 (54.5%) | 0.678 | 19 (82.6%) | 4 (30.7%) | 0.07 | 23 (100%) | 5 (62.5%) | 0.02 |
| Resistance n, (%) | 9 (40.9%) | 5 (45.5%) | 4 (17.4%) | 9 (69.3%) | 0 (0%) | 3 (37.5%) | |||
|
Age at second line treatment, years median (IQR) |
53 (20) | 43 (9) | 0.905 | 43 (7) | 34 (7) | 0.179 | 42.5 (25) | 50 (24) | 0.848 |
|
GH at second line treatment ng/mL, median (IQR) |
1.9 (7) | 2.2 (5) | 0.481 | 3.6 (4) | 4 (5) | 0.131 | 3.7 (17) | 5.2 (7) | 0.721 |
| IGF-I x ULN at second line treatment, median (IQR) | 1.6 (1.6) | 2.9 (1) | 0.5 | 2.1 (1.4) | 3.2 (1.6) | 0.001 | 1.5 (3) | 2 (0.7) | 0.339 |
| Peg-V daily dosage, median (IQR) | 15 (10) | 20 (15) | 0.57 | 20 (10) | 30 (10) | 0.002 | Na | Na | Na |
| Pasireotide Lar dosage | |||||||||
| 40 mg/monthly n, (%) | Na | Na | Na | Na | Na | Na | 10 (43.5%) | 5 (62.5%) | 0.3 |
| 60 mg/monthly n, (%) | 13 (56.5%) | 3 (37.5%) | |||||||
n.s. not stastical significant